Jason M. Silversteen, DO

Clinical Lead, Outpatient Neurology Specialists ChristianaCare

Newark DE

Jason M. Silversteen is a board-certified neurologist and holds current medical licensure in Delaware.

Contact

ChristianaCare
View more experts managed by ChristianaCare

View all Experts

Biography

Dr. Silversteen is a neurology specialist at ChristianaCare, where he is also director of the Comprehensive Multiple Sclerosis Center and serves as the clinical lead for the outpatient neurology specialists practice.

He is a board-certified neurologist and holds current medical licensure in Delaware. Dr. Silversteen has conducted clinical trials, delivered presentations and lectures, and authored papers on multiple sclerosis and its treatment to both students and practicing neurologists. He has also shared his expertise in the form of patient education and community service programs.

Areas of Expertise

Autoimmune Neurology

Neuromyelitis Optica Spectrum Disorder

Transverse Myelitis

Autoimmune Encepahlitis

MOG Antibody Disease

Education

Lake Erie College of Osteopathic Medicine

2005

Arcadia University

Biology

2001

Multimedia

Links and Image Galleries

Downloadable Photos of Dr. Jason Silversteen

Media Appearances

8 Ways to Ease MS Pain

Everyday Health online

2015-10-19

This is a great place to start. “You want to be sure you’re getting proper sleep, eating a healthy diet, and getting some form of exercise," says Dr. Silversteen. "You also want to be well rested — fatigue exacerbates pain...”

Selected Papers and Publications

No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice

Current Medical Research and Opinion

Robert Zivadinov, Nasreen Khan, Jonathan R. Korn, Ellen Lathi, Jason Silversteen, Jonathan Calkwood, Scott Kolodny, Diego Silva, Jennie Medin & Bianca Weinstock-Guttman

2018-02-02

The impact of multiple sclerosis (MS) center type on outcomes has not been investigated. This study aimed to evaluate baseline characteristics and clinical and magnetic resonance imaging (MRI) outcomes in patients with MS receiving fingolimod over 16 months’ follow-up at private or academic centers in the USA.

Assessing ‘No Evidence of Disease Activity’ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice

CNS Drugs

Bianca Weinstock-Guttman, Jennie Medin, Nasreen Khan, Jonathan R. Korn, Ellen Lathi, Jason Silversteen, Jonathan Calkwood, Diego Silva, Robert Zivadinov, On behalf of the MS-MRIUS Study Group

2017-12-21

‘No evidence of disease activity’ (NEDA), a composite measure of clinical and magnetic resonance imaging outcomes, provides a comprehensive assessment of disease activity, but is not extensively reported in clinical practice. NEDA-3 is defined as patients with no new/enlarged T2 or gadolinium-enhancing lesions, no relapses, and no disability progression (according to Expanded Disability Status Scale scores). NEDA-4 comprises the components of NEDA-3 and a fourth criterion of ≤ 0.4% annualized brain volume loss.

External Service & Affiliations

American Academy of Neurology : Member
American Osteopathic Association : Member